CANCER AND INFLAMMATION

  1. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi:10.1126/scitranslmed.aaq1093.

  2. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell 2021 Jun 10;184(12):3143-3162.e32. doi:10.1016/j.cell.2021.04.022. Epub 2021 May 17.

  3. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. JCI Insight 2019 Feb 21;4(4):e125693. doi: 10.1172/jci.insight.125693.

  4. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548.Epub 2017 May 15.

  5. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2019 Jan 1;79(1):209-219. doi: 10.1158/0008-5472.CAN-18-0717.Epub 2018 Nov 2.

  6. Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell. 2020 Jul 13;38(1):129-143.e7. doi: 10.1016/j.ccell.2020.05.003.Epub 2020 Jun 11.

  7. TBK1 and IKKε act like an OFF switch to limit NLRP3 inflammasome pathway activation. Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):e2009309118. doi: 10.1073/pnas.2009309118.

  8. The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma. J Pediatr Surg. 2023 Jun;58(6):1145-1154. doi: 10.1016/j.jpedsurg.2023.02.017.Epub 2023 Feb 17.

  9. Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123.Epub 2018 Jan 22.

  10. Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma. Cancers (Basel). 2022 Apr 13;14(8):1952. doi: 10.3390/cancers14081952.

  11. Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells. Sci Rep. 2022 Aug 13;12(1):13796. doi: 10.1038/s41598-022-18118-7.

  12. PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells. Mol Oncol 2023 Sep;17(9):1803-1820.doi: 10.1002/1878-0261.13488.Epub 2023 Jul 26.

  13. Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma. Brain Commun. 2020 Jan 11;2(1):fcaa002.doi: 10.1093/braincomms/fcaa002.eCollection 2020.

  14. Rapid Characterization of Solid Tumors Using Resonant Sensors. ACS Omega. 2022 Sep 2;7(36):32690-32700. doi: 10.1021/acsomega.2c04345.eCollection 2022 Sep 13

  15. Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34.

    doi: 10.1016/j.bmc.2015.07.007.Epub 2015 Sep 11.

  16. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest. 2012 Jul;122(7):2637-51. doi: 10.1172/JCI62058.Epub 2012 Jun 1.

NEURODEGENERATIVE DISEASES

  1. Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal Models. Neurotherapeutics. 2020 Jul;17(3):1087-1103. doi: 10.1007/s13311-020-00841-6.

  2. Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration. Review Pharmacol Ther 2019 Sep:201:181-201. doi: 10.1016/j.pharmthera.2019.05.016.

RESPIRATORY DISEASES

  1. Small-Molecule Activation of Protein Phosphatase 2A Counters Bleomycin-Induced Fibrosis in Mice. ACS Pharmacol Transl Sci. 2023 Oct 17;6(11):1659-1672. doi: 10.1021/acsptsci.3c00117.eCollection 2023 Nov 10.

  2. Protein Phosphatase 2A Reduces Cigarette Smoke-induced Cathepsin S and Loss of Lung Function. Am J Respir Crit Care Med. 2019 Jul 1;200(1):51-62. doi: 10.1164/rccm.201808-1518OC.

  3. Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases. Review. Medicina (Kaunas) 2023 Aug 26;59(9):1552. doi: 10.3390/medicina59091552.

  4. Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A. Am J Respir Cell Mol Biol 2018 Dec;59(6):695-705. doi: 10.1165/rcmb.2018-0173OC.

  5. Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema. Am J Respir Cell Mol Biol. 2023 Nov;69(5):533-544. doi: 10.1165/rcmb.2023-0105OC.

  6. Relevance of the PP2A Pathway in the Molecular Mechanisms of Chronic Obstructive Pulmonary Disease. Comment Am J Respir Cell Mol Biol. 2019 Nov;61(5):659-660.

  7. PP2A: A Novel Target to Prevent Cathepsin S-mediated Damage in Smoking-induced Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2019 Jul 1;200(1):6-8. doi: 10.1164/rccm.201901-0219ED.

  8. PP2A as a New Player in Chronic Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol. 2018 Dec;59(6):659-660. doi: 10.1165/rcmb.2018-0242ED.

  9. Putting a Novel Emphysema Treatment on the SMAP. Am J Respir Cell Mol Biol. 2023 Nov;69(5):491-492. doi: 10.1165/rcmb.2023-0263ED.